2025-09-19 - Analysis Report
Okay, here's a comprehensive analysis of Natera Inc. (NTRA) based on the data you provided.

## Natera Inc. (NTRA) Analysis - September 15, 2025

**Company Overview:** Natera Inc. is a diagnostics company that focuses on cell-free DNA testing for reproductive health, oncology, and organ health.

### 1. Performance vs. S&P 500 (VOO)

*   **NTRA Cumulative Return:** 170.43%
*   **VOO Cumulative Return:** 105.35%
*   **Absolute Deviation:** 55.0 (NTRA outperformed VOO)
*   **Relative Deviation:** 14.0 (NTRA's outperformance is at the 14th percentile of its historical deviation range)

**Analysis:** NTRA has significantly outperformed the S&P 500. However, the relative deviation indicates that the current outperformance is not exceptionally high compared to its historical range.

Here's a table summarizing the Alpha, Beta and other analysis over different years:

| Year       | CAGR   | MDD    | Alpha   | Beta | Cap(B) |
|------------|--------|--------|---------|------|--------|
| 2015-2017  | -6.0%  | 62.4%  | -31.0%  | 0.0  | 1.2    |
| 2016-2018  | 29.0%  | 80.1%  | 11.0%   | 0.0  | 1.9    |
| 2017-2019  | 159.0% | 80.1%  | 130.0%  | 1.2  | 4.5    |
| 2018-2020  | 530.0% | 80.1%  | 510.0%  | 0.3  | 13.4   |
| 2019-2021  | 355.0% | 62.9%  | 307.0%  | 0.2  | 12.6   |
| 2020-2022  | -119.0%| 62.9%  | -121.0% | 0.2  | 5.4    |
| 2021-2023  | -482.0%| 69.9%  | -500.0% | 1.1  | 8.4    |
| 2022-2024  | -75.0% | 70.6%  | -100.0% | 1.2  | 21.3   |
| 2023-2025  | 119.0% | 76.1%  | 62.0%   | 0.8  | 23.6   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows significant volatility over different periods, with extremely high growth rates in some years (e.g., 2018-2020) and substantial declines in others (e.g., 2021-2023).
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating significant risk and potential for large losses.
*   **Alpha:** Alpha values are highly variable. Positive alpha values indicate outperformance relative to the benchmark, while negative values indicate underperformance.
*   **Beta:** Beta values range from 0.0 to 1.2, suggesting that NTRA's price movements are generally less volatile than the market (Beta < 1) in some periods and more volatile (Beta > 1) in others. Beta values of 0.0 mean it does not move with the market at all
*   **Cap(B):** The market capitalization has grown significantly over time, reflecting periods of high growth.

### 2. Recent Stock Price Movement

*   **Current Price:** 175.43
*   **Last Market Data:**
    *   Price: 172.16
    *   Previous Close: 168.51
    *   Change: 2.17
*   **5-day Moving Average:** 172.98
*   **20-day Moving Average:** 168.27
*   **60-day Moving Average:** 157.31

**Analysis:** The stock is trading above its 5-day, 20-day, and 60-day moving averages, indicating an upward trend. The recent price increase from the previous close (change of 2.17) suggests positive momentum.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3324 (Low Risk)
*   **RSI:** 64.50 (Approaching overbought territory)
*   **PPO:** 0.0328 (Positive, suggesting upward momentum)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Deviation Change:** -0.4 (Short-term decrease)
*   **Expected Return (%):** 97.7% (Long-term, relative to S&P 500)

**Analysis:**

*   The Market Risk Indicator suggests low risk.
*   The RSI is approaching overbought levels, which could indicate a potential pullback.
*   The positive PPO supports the upward trend.
*   The hybrid signal suggests caution, with a recommendation to buy only a portion of available cash, considering the low MRI.
*   The negative change in relative deviation indicates a recent weakening of the stock's performance compared to the S&P 500.
*   The expected return is very high, suggesting significant long-term potential.

### 4. Recent News & Significant Events

*   **Negative News:** Several articles discuss why NTRA stock is trading lower.
*   **Positive News:** Articles highlight reasons to be a fan of NTRA and discuss potential valuation impacts from the ARCHER trial. Also, Natera is featured in a report about the liquid biopsy market.

**Analysis:** The news is mixed, with some articles focusing on short-term declines and others highlighting long-term potential and strategic advantages in the liquid biopsy market. This suggests that investor sentiment may be volatile.

### 4-2. Analyst Opinions

*   **Consensus:** Strong Buy (1.45 on a scale of 1-5)
*   **Opinions:** 20 analysts
*   **Target Price:**
    *   Average: 198.45
    *   High: 268.00
    *   Low: 37.00

**Analysis:** The analyst consensus is strongly positive, with a high average target price. However, the wide range between the high and low target prices indicates uncertainty about the stock's potential.

### 5. Recent Earnings Analysis

| Date       | EPS   | Revenue    |
|------------|-------|------------|
| 2025-08-08 | -0.74 | $0.55B     |
| 2025-05-09 | -0.50 | $0.50B     |
| 2024-11-12 | -0.26 | $0.44B     |
| 2024-08-09 | -0.30 | $0.41B     |
| 2025-08-08 | -0.30 | $0.41B     |

**Analysis:** Natera is currently not profitable, as indicated by the negative EPS. However, revenue has been generally increasing, suggesting growth in the underlying business.

### 6. Financial Information

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $0.55B   | 63.41%        |
| 2025-03-31 | $0.50B   | 63.12%        |
| 2024-12-31 | $0.48B   | 62.94%        |
| 2024-09-30 | $0.44B   | 61.79%        |
| 2024-06-30 | $0.41B   | 58.83%        |

| Quarter    | Equity   | ROE       |
|------------|----------|-----------|
| 2025-06-30 | $1.25B   | -8.10%    |
| 2025-03-31 | $1.24B   | -5.40%    |
| 2024-12-31 | $1.20B   | -4.50%    |
| 2024-09-30 | $0.88B   | -3.60%    |
| 2024-06-30 | $0.84B   | -4.48%    |

**Analysis:**

*   **Revenue:** Revenue is steadily increasing, reflecting business growth.
*   **Profit Margin:** The profit margin is high and relatively stable, indicating efficient operations.
*   **Equity:** Equity is increasing, suggesting a strengthening financial position.
*   **ROE:** The negative ROE indicates that the company is not generating profits from its equity. However, the trend is improving, with ROE becoming less negative over time.

### 7. Overall Assessment

Natera (NTRA) presents a mixed picture.

*   **Positives:** Strong analyst consensus, high expected return, increasing revenue and profit margin, and innovative position in the liquid biopsy market.
*   **Negatives:** Lack of current profitability, high volatility, approaching overbought RSI, recent negative news flow, and decreasing change in recent relative deviation.

**Recommendation:**

NTRA appears to be a high-growth, high-risk stock. The positive long-term outlook, driven by its innovative technology and market position, is tempered by current financial performance and short-term market volatility.

*   **Long-term investors:** Might consider accumulating NTRA shares, especially on dips, given the strong growth potential and analyst support. However, be prepared for significant price swings.
*   **Short-term traders:** Should be cautious, given the recent negative news and potential for a pullback from overbought conditions.

**Disclaimer:** This is an analysis based on the provided data and should not be considered financial advice. Investors should conduct their own research and consult with a financial advisor before making investment decisions.
